English | Español

Eli Lilly And Company
Patient Daily | May 25, 2023

Lilly ESG Report Highlights Progress Towards Sustainability Goals
Patient Daily | May 24, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Patient Daily | May 22, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
Patient Daily | May 9, 2023

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
Patient Daily | May 9, 2023

Lilly Declares Second-Quarter 2023 Dividend
Patient Daily | May 9, 2023

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Patient Daily | Apr 26, 2023

Lilly to Divest BAQSIMI to Amphastar
Patient Daily | Apr 26, 2023

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Trending
+ Pharmaceuticals
Patient Daily | Jun 30, 2025

PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+ Pharmaceuticals
Patient Daily | Jun 25, 2025

Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’
+ Pharmaceuticals
Patient Daily | Jul 1, 2025

PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’